4,203 results match your criteria: "Alloimmunization From Transfusions"

Increased Intrauterine Transfusion Blood Volume Needed to Correct Fetal Anemia due to Placental Chorioangioma.

Fetal Diagn Ther

September 2024

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Introduction: To compare the blood volume transfused for fetal anemia in cases of placental chorioangioma versus red blood cell (RBC) alloimmunization in patients matched for gestational age (GA) and hydrops.

Methods: Study patients had intrauterine transfusions and were obtained from 3 sources: group (1) placental chorioangioma patients treated at our center (2016-2023); group (2) placental chorioangioma patients reported in the medical literature; and group (3) RBC alloimmunization patients treated for fetal anemia at our center (2016-2023) matched (2:1) to patients in groups 1 and 2 by GA at procedure and presence of hydrops. The expected volume (cc) of transfusion was calculated for all patients based on a formula commonly used for fetal anemia in cases of RBC alloimmunization that includes the GA at procedure, pre-transfusion hemoglobin, donor hemoglobin, and target hemoglobin.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the prevalence and factors associated with red blood cell (RBC) alloimmunization in transfused patients, focusing on how clinical factors relate to the development and disappearance of RBC antibodies.
  • Data from 1194 patients across five institutions showed that 4.6% developed new antibodies after transfusion, with the number of RBC units transfused significantly influencing this outcome.
  • The research suggests that antibodies identified through specific testing methods may often fade away quickly and emphasizes the importance of thorough antibody screening, particularly for patients receiving many transfusions, to avoid missing potentially relevant antibody information.
View Article and Find Full Text PDF

RhD-positive red blood cell allocation practice to RhD-negative patients before and during the COVID-19 pandemic.

Am J Clin Pathol

September 2024

Department of Laboratory Medicine and Pathology, Center for Regenerative Biotherapeutics, Mayo Clinic, Rochester, MN, US.

Article Synopsis
  • * A survey distributed to physicians revealed that most institutions did not change their policies regarding the selection of pRBCs in RhD-negative patients during the pandemic, with 83.87% of policies remaining the same.
  • * Despite challenges in the supply of RhD-negative pRBCs, many respondents (53.85%) reported offering Rh immunoglobulin to Rh-negative patients who received RhD-positive pRBCs, indicating some variability in practices.
View Article and Find Full Text PDF

Objective: Congenital viral infection may result in fetal anemia and thrombocytopenia. While intrauterine blood transfusions (IUTs) are more commonly performed for Rh alloimmunization, reports using IUT for infection have varying success. Our primary objective was to characterize the outcomes of patients undergoing IUT for infectious etiologies at our center compared with Rh disease.

View Article and Find Full Text PDF

Background And Objectives: The identification of platelet antibodies is essential for diagnosing and managing conditions such as fetal and neonatal alloimmune thrombocytopenic purpura, post-transfusion purpura, and immune platelet refractoriness. Monoclonal antibody immobilization of platelet antigens (MAIPA) is the standard method for detecting anti-human platelet antigen (HPA) antibodies, while the detection of anti-HLA antibodies once relied on the complement-dependent cytotoxicity method, however advanced technologies such as enzyme-linked immunosorbent assay and Luminex have significantly improved sensitivity and accuracy in identifying these antibodies. Flow cytometry-based techniques (platelet immunofluorescence test - PIFT) and Luminex platform-driven microsphere-based multiplex assays (Pak-Lx) are widely employed in platelet immunology laboratories owing to their remarkable flexibility and versatility.

View Article and Find Full Text PDF

Introduction: Patients with hematologic malignancy have a higher risk of developing red blood cell (RBC) alloimmunization which can delay blood transfusion. Information on the risk factors for alloimmunization in this group is still limited. This study aimed to determine the prevalence and predictors of RBC alloimmunization among these patients.

View Article and Find Full Text PDF

Assessment of erythrocyte alloimmunization among patients treated at a Brazilian university hospital.

Hematol Transfus Cell Ther

November 2024

Instituto de Ciências Biomédicas (ICBIM), Universidade Federal de Uberlândia (UFU), Uberlândia, MG, Brazil. Electronic address:

Article Synopsis
  • This study investigates the frequency of alloimmunization among patients at a Brazilian university hospital, focusing on demographic and clinical characteristics of those with positive irregular antibody screenings.
  • Findings reveal that women were more likely to be alloimmunized, with common blood groups A and O, and anti-D, anti-E, and anti-Kell antibodies frequently detected.
  • The research emphasizes the importance of thorough antibody screening and erythrocyte immunophenotyping to enhance the safety and effectiveness of blood transfusions in clinical settings.
View Article and Find Full Text PDF
Article Synopsis
  • A study evaluated the impact of cE-matching in transfusion policies for women under 45 to reduce alloimmunization and hemolytic disease in newborns.
  • After implementing cE-matching, the occurrence of anti-c antibodies decreased significantly from 46.8 to 30.4 per 100,000 pregnancies, and anti-E antibodies decreased from 122.1 to 89.9 per 100,000 pregnancies.
  • The findings suggest that cE-matched transfusion effectively minimizes alloimmunization risks, with potential for a cK-matched strategy to further prevent these complications.
View Article and Find Full Text PDF

Hemolytic disease of the fetus and newborn-a perspective of immunohematology.

Hematol Transfus Cell Ther

November 2024

Departamento de Ciências Básicas da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil. Electronic address:

Article Synopsis
  • Hemolytic disease of the fetus and newborn is a serious health issue due to incompatibility between maternal and fetal blood, with no preventive measures for most problematic antibodies.
  • A systematic review of 75 studies revealed that 44 case reports linked the disease to 11 infant deaths, with only a 0.17% alloimmunization rate noted, alongside many intrauterine transfusions.
  • The most common antibodies involved were from the Rh, Kell, and MNS blood systems; further research is needed globally to improve diagnosis and treatment management for at-risk pregnancies.
View Article and Find Full Text PDF

Sex-based utilization and outcomes of cold-stored whole blood for trauma resuscitation: Analysis of a prospective multicenter study.

J Trauma Acute Care Surg

September 2024

From the Division of Trauma and Acute Care Surgery, Department of Surgery (S.G., J.D., C.U., S.P., A.S., K.M., M.S., K.I., M.J.M.), Los Angeles General Medical Center, Los Angeles, California; Division of Trauma and Acute Care Surgery, Department of Surgery (J.D.), Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Trauma & Critical Care Surgery, Department of Surgery (J.P.H.), WellSpan York, York; Division of Trauma and Acute Care Surgery, Department of Surgery (J.O.), Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania; and Department of Surgery (J.G.), Joint Trauma System, San Antonio, Texas.

Background: Resuscitation with cold-stored whole blood (WB) has outcome benefits, but benefits varied by patient sex is unknown. There are also concerns about alloimmunization risk for premenopausal females given WB, leading to some protocols excluding this cohort. We sought to analyze WB utilization, outcomes, and disparities by patient sex.

View Article and Find Full Text PDF

Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing.

Lancet Haematol

November 2024

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Department of Clinical Pathology, University Health Network, Toronto, ON, Canada.

Anti-KEL1 antigen (also referred to as anti-Kell, or anti-K) alloimmunisation is the second most common cause of severe haemolytic disease of the fetus and newborn, after anti-rhesus D antigen, and can cause substantial fetal morbidity and mortality. Both fetal erythropoietic suppression and haemolysis contribute to anaemia. Typically, once a clinically significant alloantibody is identified during pregnancy, antibody titration is performed as a screening test to predict the risk of anaemia and the need for maternal-fetal medicine referral.

View Article and Find Full Text PDF

Hemolytic disease of the fetus and newborn (HDFN) is caused by maternal antibodies attacking fetal blood cell antigens. Despite routine antenatal anti-D prophylaxis, intrauterine transfusions (IUTs) are still needed in some HDFN cases. We conducted a retrospective cohort study on newborns with HDFN born in the 1st Department of Obstetrics and Gynecology of the Medical University of Warsaw.

View Article and Find Full Text PDF

Objective:  Nipocalimab is a neonatal fragment crystallizable (Fc) receptor (FcRn)-blocking monoclonal antibody that inhibits placental immunoglobulin G (IgG) transfer and lowers circulating maternal IgG levels. In an open-label, single-arm, phase 2 study, nipocalimab demonstrated evidence of safety and efficacy that support further investigation in a pivotal phase 3 trial of recurrent hemolytic disease of the fetus and newborn (HDFN). The phase 3 AZALEA study aims to evaluate the efficacy and safety of nipocalimab in a larger population at risk for severe HDFN, defined as HDFN associated with poor fetal outcomes or neonatal death.

View Article and Find Full Text PDF

Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management.

Semin Thromb Hemost

August 2024

Department of Pediatrics, Unit of Pediatric Hematology, Faculty of Medicine, Gazi University, Ankara, Turkey.

Bernard-Soulier syndrome (BSS) is an inherited platelet function disorder caused by mutations in the genes that encode the glycoprotein (GP) Ibα and GPIbβ subunits, as well as the GPIX subunit in the GPIbIX complex, which is located on the platelet surface and has roles in platelet adhesion and activation. Patients with autosomal recessively inherited biallelic BSS have a homozygous or compound heterozygous expression in the GPIbα, GPIbβ, and GPIX subunits of the GPIbIX complex. Patients with autosomal dominantly inherited monoallelic BSS have a heterozygous expression in only the GPIbα and GPIbβ subunits of the GPIbIX complex.

View Article and Find Full Text PDF
Article Synopsis
  • Von Willebrand disease (VWD) is the most common genetic bleeding disorder, with platelet-type VWD (PT-VWD) being a rare variant caused by a mutation in the GPIbα receptor leading to increased platelet clearance.
  • PT-VWD is often misdiagnosed as type 2B VWD, despite requiring different treatments; platelet transfusions for PT-VWD versus VWF/FVIII concentrates for type 2B VWD.
  • New synthetic peptide therapies that target the GPIbα-VWF interaction show promise in distinguishing between these conditions and may improve diagnostics and treatment options, although current therapies are limited by cost and efficacy.
View Article and Find Full Text PDF

Investigation of Delayed Transfusion Reactions in Sickle Cell Disease Patients Polytransfused in the Brazilian Amazon.

Hematol Rep

August 2024

Programa de Pós-Graduação em Ciências Aplicadas à Hematologia da Universidade do Estado do Amazonas (PPGH-UEA), Manaus 69050-001, AM, Brazil.

Background: Sickle cell disease (SCD) affects approximately 100,000 people in the United States and millions worldwide, with the highest prevalence of 70% of SCD being found in individuals of African ethnicity. Delayed hemolytic, alloimmunization, and anamnestic transfusion reactions in multiple transfusion patients need to be investigated and managed to avoid a worsening of the patient's clinical status.

Objective: This paper aims to investigate delayed transfusion reactions in SCD patients who were polytransfused in the Brazilian Amazon.

View Article and Find Full Text PDF

Purpose Of Review: Pregnancy for people with sickle cell disease (SCD) is high risk with persistently high rates of severe maternal and fetal mortality and morbidity. Transfusion therapy is the best-studied treatment for SCD in pregnancy; hydroxyurea is not usually used because of teratogenicity concerns. In high-resource settings, red cell transfusions are likely underutilized, while in low-resource settings, they may be altogether unavailable.

View Article and Find Full Text PDF
Article Synopsis
  • Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare condition where a mother’s immune system attacks her fetus's platelets, primarily due to antibodies against the HPA-1a antigen; current prevention and treatment options are lacking.
  • A study tested the efficacy of RLYB212, a monoclonal antibody that targets HPA-1a, to see if it could eliminate HPA-1a-positive platelets after a simulated fetal-maternal hemorrhage; subjects received either RLYB212 or a placebo in a blind trial.
  • Results showed that RLYB212 significantly reduced HPA-1a-positive platelets and was well tolerated, indicating its promise as a potential
View Article and Find Full Text PDF

Background And Objectives: With increasing life expectancy and prevalence of thalassaemia, it has led to a greater need for safe blood, yet the current supply from voluntary donors is insufficient to meet this demand. Thalassaemia recipients face a significant risk of alloimmunization because of repeated exposure to foreign red cell antigens. Study aims to determine high prevalent Rh antigen negative donors in western India donor population along with what percentage of these donors are willing to become dedicated voluntary donors for thalassaemia patients.

View Article and Find Full Text PDF

Management of Red Cell Alloimmunization in Pregnancy.

Obstet Gynecol

October 2024

Department of Women's Health, Dell Medical School, UT Health Austin, and the Comprehensive Fetal Center, Dell Children's Medical Center, Austin, Texas; and the Department of Obstetrics and Gynecology, Bridgeport Hospital/Yale University, Bridgeport, Connecticut.

Rhesus immune globulin has resulted in a marked decrease in the prevalence of RhD alloimmunization in pregnancy; however, antibody formation to other red cell antigens continues to occur. Evaluation for the presence of anti-red cell antibodies should be routinely undertaken at the first prenatal visit. If anti-red cell antibodies are detected, consideration of a consultation or referral to a maternal-fetal medicine specialist with experience in the monitoring and treatment of these patients is warranted.

View Article and Find Full Text PDF

Anti-Lewis antibodies are often not clinically significant since they do not react at 37°C. These antibodies have, however, occasionally been linked to hemolytic transfusion reactions (HTR). We report a case of naturally occurring anti-Lewis-a (Le-a) in a 58-year-old patient found during routine blood grouping.

View Article and Find Full Text PDF

RhD-Alloimmunization in Adult and Pediatric Trauma Patients.

Transfus Med Rev

October 2024

Standards Development and Quality Initiatives, Association for the Advancement of Blood and Biotherapies, Bethesda, MD, USA.

The actual risk of providing RhD-positive units to RhD-negative recipients remains debatable. There is no standard of care in the United States (US) to guide transfusion decisions regarding RhD type for patients with an unknown blood type, except for women of childbearing age and neonates. The risk of alloantibody formation by an RhD-negative patient exposed to RhD-positive blood is reported to be from 3% to 70%.

View Article and Find Full Text PDF

Intrauterine transfusion under fetal analgesia: the evaluation of perinatal outcomes.

Front Pain Res (Lausanne)

July 2024

Department of Woman, Mother and Neonate, Buzzi Children's Hospital, University of Milan, Milan, Italy.

Introduction: Intrauterine transfusion is the treatment for fetal anemia resulting from maternal alloimmunization, infections (parvovirus B19 and cytomegalovirus), single demise of a monochorionic twin, chorioangioma, and other rare conditions. Fetal analgesia is mandatory to reduce movement and pain perception during the procedure. This study aims to evaluate perinatal outcomes for such procedures, following the routine use of fetal analgesia in our clinical practice.

View Article and Find Full Text PDF

Common RBC antigens in O type Tunisian blood donors and their importance in alloimmunization.

Lab Med

August 2024

Immunogenetics, Cell Therapy and Blood Transfusion Research Laboratory (LR20SP05), Department of Immunohaematology, National Blood Transfusion Centre of Tunis, University of Tunis El Manar, Tunis, Tunisia.

Background: The presence of some red blood cell (RBC) antigens may affect the preference for using type O blood in emergency situations because they may induce complex or multiple alloimmunization in special circumstances.

Methods: A subgroup of 77 type O blood Tunisian donors were genotyped for 19 common blood alleles using the single specific primer-polymerase chain reaction method. The statistical analysis was done using HaploView software.

View Article and Find Full Text PDF